EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 31 / No 5 (Mai 2015) Med Sci (Paris), 31 5 (2015) 499-505 References
Free Access
Issue
Med Sci (Paris)
Volume 31, Number 5, Mai 2015
Page(s) 499 - 505
Section M/S Revues
DOI https://doi.org/10.1051/medsci/20153105011
Published online 09 June 2015
  1. Barondes SH, Castronovo V, Cooper DN, et al. Galectins: a family of animal beta-galactoside-binding lectins. Cell 1994 ; 76 : 597–598. [CrossRef] [PubMed] [Google Scholar]
  2. Leffler H, Carlsson S, Hedlund M, et al. Introduction to galectins. Glycoconj J 2004 ; 19 : 433–440. [CrossRef] [Google Scholar]
  3. Cooper DNW. Galectinomics: finding themes in complexity. Biochim Biophys Acta 2002 ; 1572 : 209–231. [CrossRef] [PubMed] [Google Scholar]
  4. Houzelstein D, Gonçalves IR, Orth A, et al. Lgals6, a 2-million-year-old gene in mice: a case of positive Darwinian selection and presence/absence polymorphism. Genetics 2008 ; 178 : 1533–1545. [CrossRef] [PubMed] [Google Scholar]
  5. Wang JL, Gray RM, Haudek KC, Patterson RJ. Nucleocytoplasmic lectins. Biochim Biophys Acta 2004 ; 1673 : 75–93. [CrossRef] [PubMed] [Google Scholar]
  6. Rabinovich GA, Toscano MA. Turning sweet on immunity: galectin-glycan interactions in immune tolerance and inflammation. Nat Rev Immunol 2009 ; 9 : 338–352. [CrossRef] [PubMed] [Google Scholar]
  7. Hirabayashi J, Hashidate T, Arata Y, et al. Oligosaccharide specificity of galectins: a search by frontal affinity chromatography. Biochim Biophys Acta 2002 ; 1572 : 232–254. [CrossRef] [PubMed] [Google Scholar]
  8. Yang RY, Hill PN, Hsu DK, Liu FT. Role of the carboxyl-terminal lectin domain in self-association of galectin-3. Biochemistry (Mosc) 1998 ; 37 : 4086–4092. [CrossRef] [Google Scholar]
  9. Morris S, Ahmad N, André S, et al. Quaternary solution structures of galectins-1, -3, and -7. Glycobiology 2004 ; 14 : 293–300. [CrossRef] [PubMed] [Google Scholar]
  10. Lepur A, Salomonsson E, Nilsson UJ, Leffler H. Ligand induced galectin-3 protein self-association. J Biol Chem 2012 ; 287 : 21751–21756. [CrossRef] [PubMed] [Google Scholar]
  11. Gauthier L, Rossi B, Schiff C. La galectine-1 est un ligand du récepteur des lymphocytes pré-B. Med Sci (Paris) 2003 ; 19 : 144–146. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  12. Elantak L, Espeli M, Boned A, et al. Structural basis for galectin-1-dependent pre-B cell receptor (pre-BCR) activation. J Biol Chem 2012 ; 287 : 44703–44713. [CrossRef] [PubMed] [Google Scholar]
  13. Cummings RD, Liu FT. Galectins. In : Varki A, Cummings RD, Esko JD, et al., eds. Essentials of glycobiology (chapter 33). 2nd ed. Cold Spring Harbor (NY) : Cold Spring Harbor Laboratory Press, 2009. [Google Scholar]
  14. Delacour D, Koch A, Jacob R. The role of galectins in protein trafficking. Traffic 2009 ; 10 : 1405–1413. [CrossRef] [PubMed] [Google Scholar]
  15. Villeneuve C, Baricault L, Canelle L, et al. Mitochondrial proteomic approach reveals galectin-7 as a novel BCL-2 binding protein in human cells. Mol Biol Cell 2011 ; 22 : 999–1013. [CrossRef] [PubMed] [Google Scholar]
  16. Lakshminarayan R, Wunder C, Becken U, et al. Galectin-3 drives glycosphingolipid-dependent biogenesis of clathrin-independent carriers. Nat Cell Biol 2014 ; 16 : 595–606. [CrossRef] [PubMed] [Google Scholar]
  17. Gendronneau G, Sidhu SS, Delacour D, et al. Galectin-7 in the control of epidermal homeostasis after injury. Mol Biol Cell 2008 ; 19 : 5541–5549. [CrossRef] [PubMed] [Google Scholar]
  18. Georgiadis V, Stewart HJS, Pollard HJ, et al. Lack of galectin-1 results in defects in myoblast fusion and muscle regeneration. Dev Dyn 2007 ; 236 : 1014–1024. [CrossRef] [PubMed] [Google Scholar]
  19. Thijssen VL, Postel R, Brandwijk RJ, et al. Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci USA 2006 ; 103 : 15975–15980. [CrossRef] [Google Scholar]
  20. Boscher C, Zheng YZ, Lakshminarayan R, et al. Galectin-3 protein regulates mobility of N-cadherin and GM1 ganglioside at cell-cell junctions of mammary carcinoma cells. J Biol Chem 2012 ; 287 : 32940–32952. [CrossRef] [PubMed] [Google Scholar]
  21. Goetz JG, Joshi B, Lajoie P, et al. Concerted regulation of focal adhesion dynamics by galectin-3 and tyrosine-phosphorylated caveolin-1. J Cell Biol 2008 ; 180 : 1261–1275. [CrossRef] [PubMed] [Google Scholar]
  22. Hikita C, Vijayakumar S, Takito J, et al. Induction of terminal differentiation in epithelial cells requires polymerization of hensin by galectin-3. J Cell Biol 2000 ; 151 : 1235–1246. [CrossRef] [PubMed] [Google Scholar]
  23. Gendronneau G, Sanii S, Dang T, et al. Overexpression of galectin-7 in mouse epidermis leads to loss of cell junctions and defective skin repair. PLoS One 2015; 10 : e0119031. [CrossRef] [PubMed] [Google Scholar]
  24. Haudek KC, Spronk KJ, Voss PG, et al. Dynamics of galectin-3 in the nucleus and cytoplasm. Biochim Biophys Acta 2010 ; 1800 : 181–189. [CrossRef] [PubMed] [Google Scholar]
  25. Vyakarnam A, Dagher SF, Wang JL, Patterson RJ. Evidence for a role for galectin-1 in pre-mRNA splicing. Mol Cell Biol 1997 ; 17 : 4730–4737. [PubMed] [Google Scholar]
  26. Haudek KC, Patterson RJ, Wang JL. SR proteins and galectins: what’s in a name? Glycobiology 2010 ; 20 : 1199–1207. [CrossRef] [PubMed] [Google Scholar]
  27. Chen HY, Weng IC, Hong MH, Liu FT. Galectins as bacterial sensors in the host innate response. Curr Opin Microbiol 2014 ; 17 : 75–81. [CrossRef] [PubMed] [Google Scholar]
  28. Stowell SR, Arthur CM, Dias-Baruffi M, et al. Innate immune lectins kill bacteria expressing blood group antigen. Nat Med 2010 ; 16 : 295–301. [CrossRef] [PubMed] [Google Scholar]
  29. Nieminen J, St-Pierre C, Bhaumik P, et al. Role of galectin-3 in leukocyte recruitment in a murine model of lung infection by Streptococcus pneumoniae. J Immunol 2008 ; 180 : 2466–2473. [CrossRef] [PubMed] [Google Scholar]
  30. Hrynchyshyn N, Jourdain P, Desnos M, et al. Galectin-3: a new biomarker for the diagnosis, analysis and prognosis of acute and chronic heart failure. Arch Cardiovasc Dis 2013 ; 106 : 541–546. [CrossRef] [PubMed] [Google Scholar]
  31. Harazono Y, Nakajima K, Raz A. Why anti-Bcl-2 clinical trials fail: a solution. Cancer Metastasis Rev 2014 ; 33 : 285–294. [CrossRef] [PubMed] [Google Scholar]
  32. Newlaczyl AU, Yu LG. Galectin-3: a jack-of-all-trades in cancer. Cancer Lett 2011 ; 313 : 123–128. [CrossRef] [PubMed] [Google Scholar]
  33. Sanchez-Ruderisch H, Fischer C, Detjen KM, et al. Tumor suppressor p16 INK4a: downregulation of galectin-3, an endogenous competitor of the pro-anoikis effector galectin-1, in a pancreatic carcinoma model. FEBS J 2010 ; 277 : 3552–3563. [CrossRef] [PubMed] [Google Scholar]
  34. Chauhan D, Li G, Podar K, et al. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells. Cancer Res 2005 ; 65 : 8350–8358. [CrossRef] [PubMed] [Google Scholar]
  35. Clark MC, Pang M, Hsu DK, et al. Galectin-3 binds to CD45 on diffuse large B-cell lymphoma cells to regulate susceptibility to cell death. Blood 2012 ; 120 : 4635–4644. [CrossRef] [PubMed] [Google Scholar]
  36. Henderson NC, Mackinnon AC, Farnworth SL, et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol 2008 ; 172 : 288–298. [CrossRef] [PubMed] [Google Scholar]
  37. Klyosov A, Zomer E, Platt D. DAVANAT® (GM-CT-01) and colon cancer: preclinical and clinical (phase I and II) studies. In : Klyosov AA, ed. Glycobiology and drug design, vol. 1102. Washington, DC : American Chemical Society, 2012 : 89–130. [CrossRef] [Google Scholar]
  38. Astorgues-Xerri L, Riveiro ME, Tijeras-Raballand A, et al. Unraveling galectin-1 as a novel therapeutic target for cancer. Cancer Treat Rev 2014 ; 40 : 307–319. [CrossRef] [PubMed] [Google Scholar]
  39. Mackinnon AC, Gibbons MA, Farnworth SL, et al. Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3. Am J Respir Crit Care Med 2012 ; 185 : 537–546. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.